Here’s What you Should Know About Dipping Stock of Certara, Inc. (CERT) in the Aftermarket

Certara, Inc. (CERT) is a leading company providing services to patients via biosimulation software for the transformation of drug discovery and its developmental phase. Some of the core research fields of the company include empirical biosimulation, clinical pharmacology, regulatory writing, and medical communications and market access.

Top 5 Tech Stocks to Buy in 2024

Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry. "Top 5 AI Stocks to Buy in 2024."

Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"


The price of CERT stock during the regular trading on December 31, 2021, with a slight dip of 0.25% was $28.42. At last check in the aftermarket, the stock further declined by 6.76%.

CERT: Events and Happenings

On December 21, 2021, CERT reported that FDA had renewed and expanded its licenses of the exclusive biosimulation software, with additional 400 consumer licenses of Phoenix and Simcyp software. A total of FDA’s 12 divisions and offices used the company’s software for research and independent analysis, verification and reviewing the regulatory submissions.

On December 13, 2021, CERT reported the release of Pinnacle 21 Enterprise Software. It updated the Company’s leading software for preparing clinical trial data for biosimulation and regulatory submission. On December 08, 2021, CERT reported that the company hosted an Investor Day held on December 15, 2021. Company’s executive management provided updates on differentiated software and technology-driven platforms, financial guidance for 2022, and Company’s future strategies.

On December 02, 2021, CERT reported about the release of Simcyp Simulator’s 21st Version. It updated the Company’s modeling and simulation program. The Simulator was used during the development of drugs to assess new drug preparation, regulate first-in-human dosing, improve the design of clinical studies and envisage drug-drug interactions.

On November 29, 2021, CERT reported about the issuance of D360 version 21.5. It was used by researchers to cumulate multiple data sources and analysis of biological drugs. As a result, increased research efficiency, improved workflow and data handling, and advanced visualization capacity was observed.

On November 22, 2021, CERT reported about the closure of a public offering of 10,000,000 shares of the company’s common stock by shareholders at a public price of $31.00 per share. The company did not receive proceeds from the sale of shares in the offering.

Key Financials

On November 09, 2021, CERT announced its financial results for the third quarter ended September 30, 2021. Some of the key highlights are as follows.


Revenue reported by the company was $73.9 million for Q3 2021 as compared to $60.3 million for the third quarter of 2020. The revenue represented a growth of 23% over the year.

Net Loss per Share

Diluted net loss per share for Q3 2021 was $1.8 million or $0.01 per share, as compared to a net income of $1.2 million or $0.01per share for the third quarter of 2020. Net loss decreased over the year by $3.0 million.

Total Current Assets

Total current assets reported by the company for Q3 2021 were $504 million.

On November 03, 2021, CERT reported that company executives participated at the Virtual 33rd Piper Sandler Annual Healthcare Conference on November 22, 2021.


Although the price of CERT stock is 8% up from the last month, yet the company’s stock dipped in the aftermarket session. The decline in stock price is due to an uncertain market environment, restraining the investors from doing investments in the company.